share_log

HC Wainwright & Co. Reiterates Buy on Altimmune, Maintains $15 Price Target

Benzinga ·  Dec 2, 2023 03:28

HC Wainwright & Co. analyst Patrick Trucchio reiterates Altimmune (NASDAQ:ALT) with a Buy and maintains $15 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment